Nanopore sequencing for detecting reciprocal translocation carrier status in preimplantation genetic testing

BMC Genomics. 2023 Jan 2;24(1):1. doi: 10.1186/s12864-022-09103-5.

Abstract

Background: Balanced reciprocal translocation (BRT) is one of the most common chromosomal abnormalities that causes infertility, recurrent miscarriage, and birth defects. Preimplantation genetic testing (PGT) is widely used to select euploid embryos for BRT carriers to increase the chance of a healthy live birth. Several strategies can be used to distinguish reciprocal translocation carrier embryos from those with a normal karyotype; however, these techniques are time-consuming and difficult to implement in clinical laboratories. In this study, nanopore sequencing was performed in two reciprocal translocation carriers, and the results were validated using the next-generation sequencing-based method named, "Mapping Allele with Resolved Carrier Status" (MaReCs).

Results: The translocation breakpoints in both reciprocal translocation carriers were accurately identified by nanopore sequencing and were in accordance with the results obtained using MaReCs. More than one euploid non-balanced translocation carrier embryo was identified in both patients. Amniocentesis results revealed normal karyotypes, consistent with the findings by MaReCs and nanopore sequencing.

Conclusion: Our results suggest that nanopore sequencing is a powerful strategy for accurately distinguishing non-translocation embryos from translocation carrier embryos and precisely localizing translocation breakpoints, which is essential for PGT and aids in reducing the propagation of reciprocal translocation in the population.

Keywords: Breakpoints; MaReCs; Nanopore sequencing; PGT-SR; Preimplantation genetic testing; Reciprocal translocation.

MeSH terms

  • Blastocyst
  • Female
  • Fertilization in Vitro
  • Genetic Testing
  • Humans
  • Nanopore Sequencing*
  • Pregnancy
  • Preimplantation Diagnosis* / methods
  • Translocation, Genetic